Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | FYN | P06241 | 2/20 | 0.52 |
| ▸ | MMP9 | P14780 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88340 | 0.92 | LMNA (0.64) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29446988 | 0.89 | CA2 (0.62) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| SCHEMBL18197 | 0.89 | CA2 (0.62) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| Methane SCHEMBL11062496 | 0.87 | CA2 (0.59) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| SCHEMBL7806601 | 0.87 | CA2 (0.59) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| Phosphine SCHEMBL28067413 | 0.87 | CA2 (0.59) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28322857 | 0.87 | CA2 (0.59) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| SCHEMBL27854468 | 0.82 | TRPA1 (0.58) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| SCHEMBL9768108 | 0.82 | ALDH1A1 (0.50) | LMNAALOX15ALDH1A1HPGDHSD17B10 | |
| Methoxymethane SCHEMBL7185958 | 0.82 | CA2 (0.68) | LMNAALOX15ALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670485-A4 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7241905-B2 | Dioxin analogues and methods and kits for searching out dioxins-decomposing organisms or enzymes or dioxin-decomposing enzyme genes | FORESTRY AND FOREST PRODUCTS RESEARCH INSTITUTE (JP) | 2007-07-10 | — | — | US | disclosed |
| US-7241905-B2 | Dioxin analogues and methods and kits for searching out dioxins-decomposing organisms or enzymes or dioxin-decomposing enzyme genes | FORESTRY AND FOREST PRODUCTS RESEARCH INSTITUTE (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | RESVERLOGIX CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
| EP-1670484-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| EP-1670485-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034960-A1 | TREATMENT OF DISEASES ASSOCIATED WITH THE EGR-1 ENHANCER ELEMENT | RESVERLOGIX CORP. (CA) | 2005-04-21 | — | — | WO | disclosed |
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | US | disclosed |
| WO-2005032559-A1 | NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | RESVERLOGIX CORP. (CA) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080024-A1 | Nitric oxide donating derivatives for the treatment of cardiovascular disorders | NOS2, NOS3, NOS1 | LMNA 2355/4885ALOX15 206/4885ALDH1A1 971/4885 |
| US-20070099826-A1 | Treatment of diseases associated with the egr-1 enhancer element | TOE1, ATF1, ELF3 | LMNA 3441/4885ALOX15 1155/4885ALDH1A1 2978/4885 |
| US-20050080021-A1 | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders | NOS2, NOS1, NOS3 | LMNA 1781/4885ALOX15 265/4885ALDH1A1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.